CA1332352C - Therapeutic agent for prevention of intraventricular hemorrhage in premature infants - Google Patents

Therapeutic agent for prevention of intraventricular hemorrhage in premature infants

Info

Publication number
CA1332352C
CA1332352C CA000591929A CA591929A CA1332352C CA 1332352 C CA1332352 C CA 1332352C CA 000591929 A CA000591929 A CA 000591929A CA 591929 A CA591929 A CA 591929A CA 1332352 C CA1332352 C CA 1332352C
Authority
CA
Canada
Prior art keywords
factor xiii
intraventricular hemorrhage
prevention
premature infants
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000591929A
Other languages
English (en)
French (fr)
Inventor
Akira Shirahata
Minoru Uchida
Satoshi Tanaka
Kenichiro Tsumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of CA1332352C publication Critical patent/CA1332352C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA000591929A 1988-02-24 1989-02-23 Therapeutic agent for prevention of intraventricular hemorrhage in premature infants Expired - Lifetime CA1332352C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPSHO-63-39646 1988-02-24
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (1)

Publication Number Publication Date
CA1332352C true CA1332352C (en) 1994-10-11

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000591929A Expired - Lifetime CA1332352C (en) 1988-02-24 1989-02-23 Therapeutic agent for prevention of intraventricular hemorrhage in premature infants

Country Status (12)

Country Link
US (1) US5114916A (cg-RX-API-DMAC7.html)
EP (1) EP0330049B1 (cg-RX-API-DMAC7.html)
JP (1) JPH01216939A (cg-RX-API-DMAC7.html)
KR (1) KR0137476B1 (cg-RX-API-DMAC7.html)
AT (1) ATE94070T1 (cg-RX-API-DMAC7.html)
AU (1) AU613154B2 (cg-RX-API-DMAC7.html)
CA (1) CA1332352C (cg-RX-API-DMAC7.html)
DE (1) DE68908913T2 (cg-RX-API-DMAC7.html)
DK (1) DK174978B1 (cg-RX-API-DMAC7.html)
ES (1) ES2059588T3 (cg-RX-API-DMAC7.html)
IE (1) IE63656B1 (cg-RX-API-DMAC7.html)
PT (1) PT89802B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
JPH07502734A (ja) * 1991-12-31 1995-03-23 ザイモジェネティクス，インコーポレイティド 血液損失を減少する方法および組成物
DE69328228T2 (de) * 1992-04-21 2000-12-21 Ajinomoto Co., Inc. Wundheilmittel
DK0669834T3 (da) * 1992-11-12 2000-04-17 Zymogenetics Inc Anvendelse af topisk påført faktor Xlll til inhibering af blødning
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
EP1784415A2 (en) * 2004-08-27 2007-05-16 Novo Nordisk Health Care AG Purification of factor xiii polypeptides from biological materials
JP5086093B2 (ja) * 2004-11-23 2012-11-28 ジモジェネティクス、インコーポレイテッド 組換え型ヒトｘｉｉｉ因子の精製
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
NZ597089A (en) 2009-06-25 2014-05-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DK175919B1 (da) * 1986-09-19 2005-06-27 Univ Washington Ekspression af biologisk aktiv faktor XIII

Also Published As

Publication number Publication date
US5114916A (en) 1992-05-19
KR0137476B1 (ko) 1998-06-01
AU613154B2 (en) 1991-07-25
EP0330049A3 (en) 1991-01-30
JPH01216939A (ja) 1989-08-30
IE63656B1 (en) 1995-05-31
IE890580L (en) 1989-08-24
EP0330049B1 (en) 1993-09-08
PT89802A (pt) 1989-10-04
DK83889A (da) 1989-08-25
DE68908913T2 (de) 1994-01-27
EP0330049A2 (en) 1989-08-30
DK174978B1 (da) 2004-04-05
ES2059588T3 (es) 1994-11-16
AU3024389A (en) 1989-08-24
ATE94070T1 (de) 1993-09-15
DE68908913D1 (de) 1993-10-14
DK83889D0 (da) 1989-02-23
JPH0378850B2 (cg-RX-API-DMAC7.html) 1991-12-17
PT89802B (pt) 1994-04-29
KR890012659A (ko) 1989-09-18

Similar Documents

Publication Publication Date Title
CA1332352C (en) Therapeutic agent for prevention of intraventricular hemorrhage in premature infants
Johnson et al. Clinical investigation of intermediate‐and high‐purity antihaemophilic factor (factor VIII) concentrates
Bona et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia
JPS6253929A (ja) 出血抑制用医薬組成物
AU722743B2 (en) Stabilized aqueous liquid preparations of blood coagulation factor XIII
Federici et al. Von Willebrand's disease: clinical management
Leimgruber et al. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy
EP0278416B1 (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
US5554593A (en) Therapeutic agent for threatened abortion
EP0691850B1 (en) Factor xiii for treatment of skin wounds
EP0499679B1 (en) Therapeutic agent for diabetic gangrene
RU2119316C1 (ru) Способ лечения кровоизлияний во внутренние среды и оболочки глаза
WO2005017139A1 (en) Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage
JPH07316072A (ja) 妊娠中毒症治療剤
Green Hemophilia
McDaniel Focus on factors
CA2159609C (en) Factor xiii for treatment of skin wounds
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
JP2698782B2 (ja) 脳動脈瘤破裂防止剤
Eyster Hemophilia: A guide for the primary care physician
JOHNSON et al. of a Factor VIII Concentrateđ
JPH0495031A (ja) 血栓溶解活性増強剤
Convention Hemophilia management
Shapiro Clinical disorders of the factor VIII molecule
MXPA97000439A (en) Use of (s) -adenosil-l-metionine (same) and its salesphisiologically compatible for treatment of reperfusion damage activated by focal tempo ischemia

Legal Events

Date Code Title Description
MKEX Expiry